Dan Goldstaub, Co-Founder of PhaseV, shared on LinkedIn:
“An overwhelming ESMO meeting 2024 ended in Barcelona!
Lots of progress, new treatments, biomarkers and analysis tools.
Not enough tools coordinating all those into a more successful clinical trial, and that is where we, PhaseV, step in!”
Source: Dan Goldstaub/LinkedIn
More posts featuring ESMO24 on oncodaily.com